when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

18 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT825 Endpoints630 BioPharma Dive241 onclive165 Fierce Biotech92 BioSpace91 raps32 globenewswire health

therapy area

all Oncology1802 Rare Disease617 Cardiology549 Hematology545 Immunology450 Vaccines412 Pulmonology

Early Alert: Percutaneous Catheter Issue from Boston Scientific
ENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during use
fda medwatch · 6d ago↗ source
BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION
July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter…
fda recalls · 6d ago↗ source
American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter

28

395

Psychiatry & CNS340

Ophthalmology169

Infectious Disease165

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consume…

fda recalls · 6d ago↗ source

Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits

Prolonged use of the Abiomed 14Fr Low Profile Introducer may lead to thrombus formation.

fda medwatch · 13d ago↗ source

Thoracic Stent Graft Recall: Bolton Medical Removes Relay Pro System

Affected grafts may not unclasp from the delivery system. This may require conversion to open surgical repair and can result in patient death.

fda medwatch · 13d ago↗ source

Early Alert: Convenience Kit Issue from Medical Action Industries

Particulates have the potential to be introduced into blood circulation and become lodged within blood vessels.

fda medwatch · 21d ago↗ source

Infusion Pump Correction: Fresenius Kabi Issues Correction for Ivenix Large Volume Infusion Pump

A software anomaly may cause a false battery-health value. The pump should remain plugged in at all times.

fda medwatch · 23d ago↗ source

Infusion Pump Correction: Fresenius Kabi Issues Correction for dropped or jarred Ivenix Large Volume Infusion Pumps

If dropped, the Ivenix pump touchscreen may become unresponsive and should be removed from use.

fda medwatch · 23d ago↗ source

Convenience Kit Correction: Windstone Medical Packaging, Inc. Issues Correction for Convenience Kit

Certain Cardinal Health Webcol Large Alcohol Prep Pads in Custom Convenience Kits manufactured by Aligned Medical Solutions are not sterile.

fda medwatch · 24d ago↗ source

FDA approves Orca Bio’s cell therapy to improve transplant outcomes

The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded as Tregzi, an homage to the regulato…

Endpoints · 29d ago↗ source

Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront

Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...

Endpoints · 1mo ago↗ source

Lilly puts its stamp at #EHA26 with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly made a push in blood cancer at this year’s European Hematology Association meeting in Stockholm over the weekend. The drugmaker presented data for Jaypirca combined with the standard of c…

Endpoints · 1mo ago↗ source

Incyte CEO sees $2B Vega deal aiding a post-Jakafi future

Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…

Endpoints · 1mo ago↗ source

#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say

CHICAGO — Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved ...

Endpoints · 2mo ago↗ source

Agios ends development of tebapivat in low-risk MDS following subpar results

Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…

Endpoints · 2mo ago↗ source

AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase

AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...

Endpoints · 2mo ago↗ source

FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...

Endpoints · 2mo ago↗ source

Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud

Novo Nordisk’s GLP-1 pill works in kids with diabetes: Type 2 diabetes patients aged 10 to 17 who took Rybelsus for about six months had a statistically significant 0.83% cut in their blood sugar l…

Endpoints · 3mo ago↗ source